Menovo(SH:603538) Ge Long Hui A P P·2025-12-18 08:10Core Viewpoint - The company Menohua has received approval from the National Medical Products Administration for its atorvastatin calcium raw material drug, which will enhance its product line and expand its business scope [1] Group 1: Regulatory Approval - Menohua's subsidiary Xuancheng Menohua received the approval notice for atorvastatin calcium raw material drug with registration number Y20240000440 [1] - The application for the drug was submitted to the CDE on May 16, 2024, and it passed the review on December 17, 2025, with a registration status marked as "A" [1] Group 2: Financial Investment - The total R&D investment for the atorvastatin calcium raw material drug amounted to 14.9496 million yuan (approximately 2.1 million USD) [1] Group 3: Business Impact - The approval of atorvastatin calcium will enrich the product line of the subsidiary and help expand the company's business areas [1] - It will further enhance the integrated production capabilities of the company in the raw material drug formulation sector [1]